CARY, N.C., April 1 /PRNewswire-FirstCall/ -- Inveresk Research Group, Inc. announced today that its principal stockholder yesterday agreed to sell 5,000,000 shares of Inveresk Research common stock at an initial price to the public of $26.75 per share. The offering is comprised entirely of shares being offered by such principal stockholder. The underwriter for the offering is Goldman, Sachs & Co.
This press release does not constitute an offer of the securities described herein. A registration statement relating to the securities has been previously declared effective by the Securities and Exchange Commission. The offering is being made solely by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained from Goldman Sachs & Co., 85 Broad Street, New York, NY 10004, Attention: Prospectus Department.
Inveresk is a leading provider of drug development services to companies in the pharmaceutical and biotechnology industries. The company is based in Cary, North Carolina with facilities in Edinburgh, Scotland and Montreal, Canada.
Inveresk Research Group, Inc.
CONTACT: Matt Dallas of Financial Dynamics, +1-212-850-5627,firstname.lastname@example.org, for Inveresk Research Group, Inc.